| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010] |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA280: Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [April 2013] |
| Abemaciclib tablets |
08.01.05 |
Restricted Use
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019) |
| Abemaciclib tablets |
08.01.05 |
Restricted Use
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019) |
| Abiraterone Acetate |
08.03.04.02 |
Restricted Use
|
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (July 2016) |
| Abiraterone Acetate |
08.03.04.02 |
Restricted Use
|
NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (July 2016) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010] |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008] |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) |
| Adalimumab Subcutaneous Injection |
01.05.03 |
Restricted Use
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010) |
| Adalimumab Subcutaneous Injection |
01.05.03 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017) |
| Adalimumab Subcutaneous Injection |
01.05.03 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Adefovir Dipivoxil |
05.03.03 |
Non Formulary
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Afatinib |
08.01.05 |
Restricted Use
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014) |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration (July 2013) |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (February 2014) |
| Aflibercept |
11.08.02 |
Restricted Use
|
TA346: Aflibercept for treating diabetic macular oedema (July 2015) |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014) |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (September 2016) |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486: Aflibercept for treating choroidal neovascularisation (November 2017) |
| Alectinib capsules |
08.01.05 |
Restricted Use
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018) |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis (February 2018)) |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016) |
| Alitretinoin |
13.05.01 |
Non Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alogliptin |
06.01.02.03 |
Formulary
|
NICE NG28:Type 2 diabetes in adults: management (May 2017) |
| Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264: Alteplase for treating acute ischaemic stroke (September 2012) |
| Aluminimum Hydroxide |
01.01.01 |
Non Formulary
|
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Aluminimum Hydroxide |
01.01.01 |
Non Formulary
|
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Aluminimum Hydroxide |
01.01.01 |
Non Formulary
|
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016) |
| Aluminimum Hydroxide |
01.01.01 |
Non Formulary
|
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Amitriptyline |
04.07.03 |
Formulary
|
NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings (April 2018) |
| Amoxicillin |
05.01.01.03 |
Formulary
|
Adult Antibiotic Prescribing Guidance – Eye, Nose and Throat (ENT) infections - follow national guidance |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG164: Familial Breast Cancer (updated March 2017) |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TAG156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with non-valvular atriall fibrillation (February 2013) |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015) |
| Apixaban |
02.08.02 |
Formulary
|
NICETA 245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012) |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA372: Apremilast for treating Psoriatic arthritis (December 2015) |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis (Nov 2016) |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA368: Apremilast for treating moderate to severe plaque psoriasis (November 2015) |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis (Feb 2017) |
| Atezolizumab infusion |
08.01.05 |
Restricted Use
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019) |
| Atezolizumab infusion |
08.01.05 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017) |
| Atezolizumab infusion |
08.01.05 |
Restricted Use
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018) |
| Atezolizumab infusion |
08.01.05 |
Restricted Use
|
NICE TA638:Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (July 2020) |
| Atezolizumab infusion |
08.01.05 |
Restricted Use
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018) |
| Axitinib |
08.01.05 |
Restricted Use
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015) |
| Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011) |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Bempedoic acid |
02.12 |
Restricted Use
|
NICE TA 694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (April 21) |
| Bempedoic acid with Ezetimibe |
02.12 |
Restricted Use
|
NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (April 2021) |
| Bendamustine |
08.01.01 |
Restricted Use
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011) |
| Bendamustine |
08.01.01 |
Restricted Use
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017) |
| Benralizumab |
03.04.02 |
Restricted Use
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma (March 2019) |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend] |
| Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend] |
| Bivalirudin |
02.08.01 |
Non Formulary
|
NICE TA230: Bivalirudin for the treatment of STEMI, 2011 |
| Boceprevir |
05.03.03.02 |
Restricted Use
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C (April 2012) |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011) |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015) |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007) |
| Bosutinib |
08.01.05 |
Restricted Use
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016) |
| Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (October 2019) |
| Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA260: Botox for migraine prophylaxis June 2012) |
| Brentuximab infusion |
08.01.05 |
Restricted Use
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019) |
| Brentuximab infusion |
08.01.05 |
Restricted Use
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017) |
| Brentuximab infusion |
08.01.05 |
Restricted Use
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017) |
| Brentuximab infusion |
08.01.05 |
Restricted Use
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (August 2020) |
| Brentuximab infusion |
08.01.05 |
Restricted Use
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018) |
| Brigatinib tablets |
08.01.05 |
Restricted Use
|
NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019) |
| Brodalumab |
10.01.03 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis (March 2018) |
| Budesonide |
01.05.02 |
Restricted Use
|
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis |
| Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016) |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. (May 2016) |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes (June 2014) |
| Capecitabine |
08.01.03 |
Restricted Use
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) |
| Capecitabine |
08.01.03 |
Restricted Use
|
NICE TA191: Capecitabine for the treatment of advanced gastric cancer (July 2010) |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017) |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Ceritinib capsules |
08.01.05 |
Restricted Use
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016) |
| Ceritinib capsules |
08.01.05 |
Restricted Use
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018) |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (May 2017) |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (Januray 2016) |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis (April 2019) |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA186: Certolizumab pegol for the treatment of rheumatoid arthritis [February 2010] |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009) |
| Cetuximab |
08.01.05 |
Restricted Use
|
TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017) |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only) |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017) |
| Ciclosporin 0.1% |
11.99.99.99 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (Dec 2015) |
| Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy [January 2007] |
| Collagenase clostridium histolyticum injection |
10.03.01 |
Restricted Use
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018) |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016) |
| Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016) |
| Dabigatran etexilate |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012) |
| Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364: Daclatasvir for treating chronic hepatitis C (November 2015) |
| Dacomitinib |
08.01.05 |
Restricted Use
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019) |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA597 Dapagliflozin with insulin for treating Type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA288: Type 2 diabetes - Dapagliflozin combination therapy (June 2013) |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes (Nov 2016) |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016) |
| Dapagliflozin Tablets |
02.05.05 |
Restricted Use
|
NICE TA679 Dapagliflozin for treating chronic heart failure with reduced ejection fraction |
| Daratumumab infusion |
08.01.05 |
Restricted Use
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018) |
| Daratumumab infusion |
08.01.05 |
Restricted Use
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019) |
| Darbepoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014] |
| Dasabuvir |
05.03.03.02 |
Restricted Use
|
NICE TA365: Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C (Nov 2015) |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016) |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016) |
| Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA241:CML for whom treatment with imatinib has failed because of intolerance |
| Degarelix Injection |
08.03.04.02 |
Restricted Use
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer (August 2016) |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women (2010) |
| Dexamethasone |
04.06 |
Restricted Use
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018) |
| Dexamethasone |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema (July 2011) |
| Dexamethasone |
11.04.01 |
Restricted Use
|
NICE TA460:Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017) |
| Dexamethasone |
11.04.01 |
Restricted Use
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema (July 2015) |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (August 2014) |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis (September 2017) |
| Dipyridamole |
02.09 |
Restricted Use
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (December 2010) |
| Dipyridamole and Aspirin |
02.09 |
Restricted Use
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (December 2010) |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006) |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018) |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) |
| Donepezil |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018) |
| Doxorubicin Hydrochloride |
08.01.02 |
Restricted Use
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) |
| Doxycycline |
05.01.03 |
Formulary
|
Adult Antibiotic Prescribing Guidance – Eye, Nose and Throat (ENT) infections - follow national guidelines |
| Dronedarone |
02.03.02 |
Restricted Use
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation (updated Dec 2012) |
| Dupilumab |
13.05.03 |
Restricted Use
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis (August 2018) |
| Durvalumab |
08.01.05 |
Restricted Use
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019) |
| Eculizumab Injection |
09.01.03 |
Restricted Use
|
NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome [January 2015] |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355 - Edoxaban for preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation (Sept 2015) |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (Aug 2015) |
| Elbasvir-grazoprevir |
05.03.03.02 |
Restricted Use
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C (Oct 2016) |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (July 2013) |
| Eltrombopag |
09.01.04 |
Non Formulary
|
NICE guidance 2010 |
| Eluxadoline |
01.04.02 |
Formulary
|
TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea (August 2017) |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes (March 2015) |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016) |
| Entecavir |
05.03.03.01 |
Restricted Use
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B (Aug 2008) |
| Entecavir |
05.03.03 |
Non Formulary
|
NICE TA153: Hepatitis B - entecavir |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA316: Enzalutamide for metastatic hormone-relapsed prostate cancer, previously treated with docetaxel-containing regimen (July 2014) |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer (May 2019) |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (January 2016) |
| Eplerenone |
02.02.03 |
Restricted Use
|
NICE CG108: Chronic heart failure in adults: management (Aug 2010) |
| Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014] |
| Epoetin beta |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014] |
| Epoetin zeta |
09.01.03 |
Restricted Use
|
NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016) |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018) |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015) |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011) |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012) |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (June 2019) |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (March 2019) |
| Erythromycin |
05.01.05 |
Formulary
|
Adult Antibiotic Prescribing Guidance – Eye, Nose and Throat (ENT) infections - follow national guidance |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab [August 2010] |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010] |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) |
| Etanercept |
13.05.03 |
Non Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etelcalcetide |
06.06.01 |
Formulary
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism (June 2017) |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only] |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016) |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015) |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only] |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only] |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only] |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016) |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016) |
| Exenatide |
06.01.02.03 |
Restricted Use
|
NG28:Type 2 diabetes in adults: management (May 2017) |
| Ezetimibe |
02.12 |
Restricted Use
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (Febuary 2016) |
| Febuxostat |
10.01.04 |
Restricted Use
|
NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout [December 2008] |
| Filgotinib |
10.01.03 |
Restricted Use
|
NICE TA676 Filgotinib for treating moderate to severe rheumatoid arthritis (Feb 21) |
| Fingolimod |
08.02.04 |
Non Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Restricted Use
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (September 2001) |
| Fludarabine Phosphate |
08.01.03 |
Restricted Use
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007) |
| Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA301:Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (November 2013) |
| Fluticasone and salmeterol |
03.02 |
Formulary
|
NICE TA138: Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults and Children over 12 years (March 2008) |
| Fondaparinux Sodium |
02.08.01 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI: early management (Updated Nov 13) |
| Fremanezumab |
04.07.04.02 |
Restricted Use
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (December 2011) |
| Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (January 2018) |
| Galantamine |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018) |
| Galcanezumab |
04.07.04.02 |
Restricted Use
|
NICE TA659: Galcanezumab for preventing migraine |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010) |
| Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015) |
| Gemcitabine |
08.01.03 |
Restricted Use
|
NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer (May 2001) |
| Gemcitabine |
08.01.03 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017) |
| Gemcitabine |
08.01.03 |
Restricted Use
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer (January 2007) |
| Glecaprevir/pibrentasvir tablets |
05.03.03.02 |
Restricted Use
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C (January 2018) |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA233: Golimumab for the treatment of ankylosing spondylitis [August 2011] |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs [June 2011] |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis (January 2018) |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis [April 2011] |
| Golimumab Subcutaneous Injection |
01.05.03 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Guselkumab |
10.01.03 |
Restricted Use
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis (June 2018) |
| Human anti-D immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Routine antenatal anti-D prophylaxis for women who are rhesus D negative (August 2008) |
| Ibandronic Acid |
06.06.02 |
Restricted Use
|
NICE TA464: Bisphosphonates for treating osteoporosis (February 2018) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018) |
| Ibrutinib |
08.01.05 |
Restricted Use
|
Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017) |
| Idelalisib |
08.01.05 |
Restricted Use
|
NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019) |
| Idelalisib |
08.01.05 |
Restricted Use
|
NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015) |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016) |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010) |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016) |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010) |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199:Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010] |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008] |
| Infliximab |
13.05.03 |
Non Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab infusion |
01.05.03 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) |
| Infliximab infusion |
01.05.03 |
Restricted Use
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis (December 2008) |
| Infliximab infusion |
01.05.03 |
Restricted Use
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010) |
| Irinotecan Hydrochloride |
08.01.05 |
Restricted Use
|
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017) |
| Irinotecan Hydrochloride |
08.01.05 |
Restricted Use
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014) |
| Ivabradine |
02.06.03 |
Non Formulary
|
NICE Guidance on Stable Angina |
| Ivabradine |
02.06.03 |
Restricted Use
|
NICE TA267: Ivabradine for treating chronic heart failure (Nov 2012) |
| Ixazomib |
08.01.05 |
Restricted Use
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018) |
| Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (August 2018) |
| Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis (April 2017) |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib 20mg/mL oral solution |
08.01.05 |
Restricted Use
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (June 2009) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma (April 2020) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019) |
| Liraglutide |
06.01.02.03 |
Restricted Use
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2020) |
| Liraglutide |
06.01.02.03 |
Restricted Use
|
NICE TA 664: Liraglutide for managing overweight and obesity (Dec 2020) |
| Liraglutide |
04.05.01 |
Restricted Use
|
NICE TA 664: Liraglutide for managing overweight and obesity (Dec 2020) |
| Lorlatinib |
08.01.05 |
Restricted Use
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020) |
| Memantine |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018) |
| Metformin |
06.01.02.02 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management (May 2017) |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple sclerosis in adults: management (October 2014) |
| Metronidazole |
05.01.11 |
Formulary
|
Adult Antibiotic Prescribing Guidance – Eye, Nose and Throat (ENT) infections - follow national guidance |
| Mirabegron MR Tablets |
07.04.02 |
Restricted Use
|
NICE TA 290 Mirabegron treatment of overactive bladder |
| Mycophenolate Mofetil |
08.02.01 |
Restricted Use
|
NICE TA85 - Immunosuppressive therapy for renal transplantation in adults (September 2004) |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) |
| Naloxegol |
01.06.06 |
Restricted Use
|
NICE TA345: Naloxegol for treating opioid-induced constipation (July 2015) |
| Naltrexone Hydrochloride |
04.10.03 |
Non Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone/bupropion (8mg/90mg) |
04.05 |
Non Formulary
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity (December 2017) |
| Natalizumab |
08.02.04 |
Non Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012) |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016) |
| Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016) |
| Nintedanib capsules |
08.01.05 |
Restricted Use
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016) |
| Nintedanib capsules |
08.01.05 |
Restricted Use
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015) |
| Niraparib |
08.01.05 |
Restricted Use
|
TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019) |
| Nivolumab |
08.01.05 |
Restricted Use
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018) |
| Nivolumab |
08.01.05 |
Restricted Use
|
TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (May 2019) |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis (April 2017) |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma (March 2018) |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (May 2020) |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017) |
| Ocriplasmin |
11.08.02 |
Restricted Use
|
NICE TA 297: Ocriplasmin for treating vitreomacular traction (October 2013) |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (August 2019) |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (January 2020) |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016) |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating severe persistent allergic asthma (April 2013) |
| Ombistavir/paritaprevir/ritonavir |
05.03.03.02 |
Restricted Use
|
NICE TA365: Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C (November 2015) |
| Osimertinib mesylate |
08.01.05 |
Restricted Use
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016) |
| Oxaliplatin |
08.01.05 |
Restricted Use
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) |
| Oxaliplatin |
08.01.05 |
Restricted Use
|
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015) |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017) |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003) |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) |
| Palbociclib |
08.01.05 |
Restricted Use
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017) |
| Palbociclib |
08.01.05 |
Restricted Use
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020) |
| Panitumumab infusion |
08.01.05 |
Restricted Use
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017) |
| Panobinostat |
08.02.04 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least two previous treatments (January 2016) |
| Patiromer sorbitex calcium |
09.02.01.01 |
Formulary
|
NICE TA 623: Patiromer for treating hyperkalaemia (Feb 2020) |
| Pazopanib |
08.01.05 |
Non Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE guidance on pegaptanib in AMD (August 2008) |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (August 2006) |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010) |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (November 2013) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (September 2019) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only] |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (September 2020) |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only] |
| Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only] |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016) |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer (August 2017) |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (September 2009) |
| Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008) |
| Pentosan polysulphate capsules |
07.04.03 |
Restricted Use
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome (November 2019) |
| Pertuzumab |
08.01.05 |
Restricted Use
|
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018) |
| Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016) |
| Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019) |
| Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018) |
| Phenoxymethylpenicillin |
05.01.01.01 |
Formulary
|
Adult Antibiotic Prescribing Guidance – Eye, Nose and Throat (ENT) infections - follow national guidance |
| Pimecrolimus |
13.05.03 |
Non Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pioglitazone |
06.01.02.03 |
Formulary
|
NICE NG49: Non-alcoholic fatty liver disease (NAFLD): assessment and management (July 2016) |
| Pipericillin and Tazobactam |
05.01.01.04 |
Restricted Use
|
NICE CG151: Neutropenic sepsis: prevention and management in people with cancer (Sept 2012) |
| Pixantrone intravenous infusion |
08.01.02 |
Restricted Use
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma (February 2014) |
| Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017) |
| Ponatinib |
08.01.05 |
Restricted Use
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017) |
| Prasugrel |
02.09 |
Restricted Use
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014) |
| Pregabalin |
04.07.03 |
Restricted Use
|
NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings (April 2018) |
| Prucalopride |
01.06.07 |
Restricted Use
|
NICE TA 211: Prucalopride for the treatment of chronic constipation in women (December 2010) |
| Raloxifene Hydrochloride |
06.04.01.01 |
Restricted Use
|
NICE CG164: Familial Breasr Cancer (updated March 2017) |
| Raloxifene Hydrochloride |
06.04.01.01 |
Restricted Use
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Raloxifene Hydrochloride |
06.04.01.01 |
Restricted Use
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (May 2012) |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA237: Ranibizumab for the treatment of diabetic macular oedema (Nov 2011) |
| Ranolazine |
02.06.03 |
Restricted Use
|
NICE CG126: Stable angina: management (Aug 2016) |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE guidance, 2011 |
| Ribavirin |
05.03.03.02 |
Restricted Use
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (Sept 2010) |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribociclib |
08.01.05 |
Restricted Use
|
TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019) |
| Ribociclib |
08.01.05 |
Restricted Use
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017) |
| Riluzole |
04.09.03 |
Restricted Use
|
NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (January 2001) |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis (February 2018) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (February 2008) |
| Rituximab |
08.02.03 |
Formulary
|
TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA65 Rituximab for agressive non-Hodgkins lymphoma (September 2003) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012) |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010] |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after Acute Coronary Syndrome (March 2015) |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (May 2012) |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement surgery in adults (April 09) |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013) |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (July 2012) |
| Rivastigmine |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018) |
| Roflumilast |
03.03.03 |
Non Formulary
|
NICE Final Appraisal Determination Dec 2011 |
| Roflumilast |
03.03.03 |
Restricted Use
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease (July 2017) |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (Updated May 2014) |
| Romiplostim |
09.01.04 |
Non Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib tablets |
08.01.05 |
Restricted Use
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019) |
| Ruxolitinib |
08.01.05 |
Restricted Use
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016) |
| Sacubitril and Valsartan |
02.05.05.02 |
Restricted Use
|
NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (April 2016) |
| Sarilumab |
10.01.03 |
Restricted Use
|
Sarilumab for moderate to severe rheumatoid arthritis (November 2017) |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (May 2017) |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with NSAIDs or TNF-alpha inhibitors (September 2016) |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis (July 2015) |
| Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA330 Sofosbuvir for treating chronic hepatitis C (Feb 2015) |
| Sofosbuvir/ledipasvir |
05.03.03.02 |
Restricted Use
|
NICE TA363: Ledipasvir-sofosbuvir for treating chronic hepatitis C (November 2015) |
| Sofosbuvir/velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir-velpatasvir for treating chronic hepatitis C (January 2017) |
| Sofosbuvir-velpatasvir-voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency (2003) |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (2010) |
| Sorafenib |
08.01.05 |
Non Formulary
|
NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA178: Renal cell carcinoma |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Tacrolimus |
13.05.03 |
Non Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG164: Familial Breast Cancer (updated March 2017) |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C (April 2012) |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA23: Brain cancer - temozolomide |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tenofovir Disproxil |
05.03.03.01 |
Restricted Use
|
NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009) |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018) |
| Thalidomide |
08.02.04 |
Restricted Use
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (July 2011) |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction (December 2016) |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA236 - Ticagrelor for the Treatment of Acute Coronary Syndromes (October 2011) |
| Tiotropium |
03.01.02 |
Formulary
|
NICE ESNM55: Asthma - tiotropium (March 2015) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis (April 2018) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis [February 2012] |
| Tofacitinib |
01.05.03 |
Restricted Use
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (November 2018) |
| Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis (October 2017) |
| Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (October 2018) |
| Topiramate |
04.08.01 |
Restricted Use
|
NICE CG150: Headaches in over 12s: diagnosis and management (Nov 2015) |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009) |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA222- ovarian cancer |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002) |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012) |
| Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010) |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018) |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (June 2020) |
| Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017) |
| Trifluridine-tipiricil |
08.01.03 |
Restricted Use
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer (August 2016) |
| Upadacitinib |
10.01.03 |
Restricted Use
|
NICE TA 665 - Upadacitinib for treating severe rheumatoid arthritis (Dec 2020) |
| Ustekinumab |
10.01.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017) |
| Ustekinumab |
10.01.03 |
Restricted Use
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis (updated March 2017) |
| Ustekinumab |
10.01.03 |
Restricted Use
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis [June 2015] |
| Ustekinumab injection |
01.05.03 |
Restricted Use
|
TA633: Ustekinumab for treating moderately to severely active ulcerative colitis (June 2020) |
| Ustekinumab injection |
01.05.03 |
Restricted Use
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment (July 2017) |
| Varenicline |
04.10.02 |
Restricted Use
|
NICE TA123: Varenicline for smoking cessation (July 2007) |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis (June 2015) |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy (August 2015) |
| Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017) |
| Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019) |
| Venlafaxine |
04.03.04 |
Formulary
|
NICE CG90: Depression in adults: Recognition and Management (Updated April 2016) |
| VibeX Rapid (Riboflavin 0.1%) |
11.08.02 |
Restricted Use
|
NICE IPG466: Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (September 2013) |
| Vitamin B Compound Strong |
09.06.02 |
Formulary
|
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (February 2011) |
| Vortioxetine |
04.03.04 |
Restricted Use
|
NICE TA367: Vortioxetine for treating major depressive episodes (November 2015) |
| Zoledronic Acid (5mg/100ml) |
06.06.02 |
Restricted Use
|
NICE TA464: Bisphosphonates for treating osteoporosis (February 2018)) |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (April 2004) |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (April 2004) |
